Horizon Discovery
MDIC Launches Initiative to Improve Accuracy of Next-Generation Sequencing-Based Cancer Diagnostics
As part of the initiative, MDIC will manufacture, validate, and distribute reference samples to support the validation of NGS-based cancer diagnostics.
Sigma-Aldrich Licenses CRISPR-Cas9 Tech to Horizon Discovery
The deal enables Horizon to support gene editing researchers who need cell-line engineering beyond loss-of-function CRISPR studies into CRISPR-mediated targeted knock-in.
Horizon Discovery Licenses Gene-Edited Cell Line to Sanyou Biopharmaceuticals
Sanyou will use the cell line in the development of preclinical antibody drug projects and to support its customers' human biotherapeutic products.
PerkinElmer to Buy Horizon Discovery for $383M
The deal allows PerkinElmer to expand its portfolio of automated life sciences discovery and applied genomics products to include gene editing and gene modulation tools.
Horizon Discovery H1 Revenues Fall 14 Percent
The gene editing and gene modulation technologies firm attributed the decline to the impact of the SARS-CoV-2 pandemic on its research reagents business.